Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
172
resultados
Última actualización
04/05/2025 [06:51:00]
Resultados 75 a 100 de 172
Resumen de: AU2022463987A1
The present invention relates to combination therapies for treating cancer, optionally chemotherapy-resistant cancers, in a subject. The combination therapies comprise (a) an antibody or antigen-binding portion thereof that specifically binds to CD40, and (b) chemotherapy. The invention also relates to pharmaceutical compositions, kits and methods of using such therapies.
Resumen de: MX2024012617A
Provided herein are methods for enhancing gene therapy in an individual by administering an IRAK degrader with the gene therapy to suppress innate immunity to the gene therapy. In some embodiments, the gene therapy uses an adeno-associated virus (AAV) vector, an adenovirus vector, a lentivirus vector, a Herpes simplex virus (HSV) vector or a lipid nanoparticle. Also provided herein are methods for selecting an individual for treatment with an IRAK degrader in combination with a gene therapy agent.
Resumen de: MX2024012693A
The present disclosure relates generally to the field of molecular virology, and in particular relates to nucleic acid molecules encoding a modified alphavirus viral genome or self-replicating RNA construct (srRNA), recombinant cells and pharmaceutical compositions containing the same, as well as the use of such nucleic acid molecules, recombinant cells and compositions for the production of desired products in cell cultures or in a living body. Also provided are methods of eliciting an immune response in a subject in need thereof, as well as methods of preventing and/or treating rabies virus infection.
Resumen de: MX2024012616A
Provided herein are methods for enhancing gene therapy in an individual by administering an IRAK modulator (e.g., an IRAK-4 degrader) with the gene therapy to suppress innate immunity to the gene therapy. In some embodiments, the gene therapy uses an adeno- associated virus (AAV) vector, an adenovirus vector, a lentivirus vector, a Herpes simplex virus (HSV) vector or a lipid nanoparticle. Also provided herein are methods for selecting an individual for treatment with an IRAK modulator in combination with a gene therapy agent.
Resumen de: CN118843456A
The present disclosure relates to a plurality of spherical nanostructures. Each nanostructure comprises a central portion comprising a polymer backbone according to monomer residues of {(OR1) (OR2) PO} 2-(C) {(CH2) mSi (OR3) 3} {(CH2) mSi (OR3) 3} wherein each R1 and R2 are independently selected from the group consisting of a negative charge and H; each R3 is independently selected from the group consisting of a negative charge, H, and a covalent bond bound to a polymer backbone; wherein at least 3 R3 are bonds bound to the polymer backbone; and m is an integer between 1 and 5; and wherein the central portion of the nanostructure has a volume average hydrodynamic diameter of 10 nm to 90 nm; and an anchor layer surrounding the central portion, where the anchor layer includes a polymer according to monomer residues of (RO) 3Si-(CH2) n-Si (OR) 3, where each R is independently selected from the group consisting of negative charges, H, and covalent bonds, wherein at least two R are independently selected from the group consisting of a covalent bond bonded to a monomer residue of the central portion and a covalent bond bonded to a monomer residue of the anchor layer; wherein-represents a covalent bond; n is 1 or 2; and wherein the anchoring layer has a thickness of from 1 nm to 5 nm. The present disclosure also relates to methods of making such nanostructures as well as uses of the nanostructures, and to pharmaceutical compositions comprising such nanostructures.
Resumen de: CN118843482A
The present disclosure relates to a plurality of nanostructures having an average hydrodynamic diameter between 20 nm and 50 nm, wherein each nanostructure is a polymeric nanostructure comprising a central portion, an anchor layer surrounding the central portion, and a coating surrounding the anchor layer. The disclosure also relates to the use of such a plurality of nanostructures as a medicament, in particular for cancer treatment and/or imaging, as well as the use of such nanostructures as carriers for radionuclides. The present disclosure also relates to methods and kits for radiolabeling such nanostructures with multivalent cationic radionuclides.
Resumen de: CN119896731A
本发明属于光热材料制备技术领域，具体涉及一种液态金属纳米颗粒光热材料的制备方法，包括：步骤1、配制海藻酸钠水溶液；步骤2、在海藻酸钠水溶液中加入镓基液态金属，先通过搅拌混合，再通过超声处理充分混合；步骤3、干燥后得到生成物。本发明的制备过程是在常规环境下制备，对环境的要求低。另外，本发明制备的纳米颗粒具有稳定性好、光热性能佳、制备方法简单、形成速率快、易控制的特点，可制备具有高效光热能力的材料。综合以上有益效果，本发明在光热材料制备技术领域具有良好的应用前景。
Resumen de: CN119899218A
本文描述了作为光热转导剂的环金属化铁(II)络合物。所公开的络合物表现出高结构稳健性和在近红外(NIR)和可见光区域的显著吸收。所描述的络合物可以自组装以形成金属超分子粒子，其具有优异的光热性能并可以通过EPR效应靶向肿瘤。例如，本文公开的Fe NP具有强的近红外(NIR)吸光度，在近红外(例如，808nm)激光照射下具有至少30％(例如约60％)的高光热转换效率和/或优异的光热稳定性。Fe NP可以用包衣剂(例如牛血清白蛋白)包衣以形成包衣的Fe NP，这可以进一步增强金属超分子粒子在体内的肿瘤积累和生物相容性。Fe NP的优异光热性能使其能够解决与大多数现有光热材料相关的光热转换效率低的问题。
Resumen de: CN119896651A
本发明属于生物技术技术领域，具体涉及一种基于磷酸钙介导的外泌体药物递送系统，并进一步公开其制备方法与应用。本发明所述基于磷酸钙介导的外泌体药物递送系统，通过Ca2+和磷酸盐构建形成磷酸钙介导的外泌体递送体系，通过氯化钙转染miRNA后可以将核酸药物载入到外泌体中，外泌体中miRNA的含量显著提高，进而借助于外泌体的递送性能将药物运输，有效提高了药物的载药效率和递送效率，具有装载效率高的优势。
Resumen de: CN119899835A
本申请公开了一种高效表达GBA1的mRNA及其应用。本申请高效表达GBA1的mRNA由5’端至3’端依序包括5’甲基化帽子、5’UTR、目的基因序列、3’UTR和polyA尾巴；其中，目的基因序列为编码GBA1蛋白或GBA1突变蛋白的序列。本申请高效表达GBA1的mRNA，通过修改mRNA不同元件来获得更稳定、表达效率更高的GBA1mRNA。
Resumen de: CN119899206A
本发明公开了一种基于脐带间充质干细胞囊泡负载I型光敏前药的纳米囊泡及其制备方法与应用，其包括来源于人脐间充质干细胞的囊泡及其负载的所述I型光敏前药。本发明的优点包括：纳米囊泡EVs@NBS‑PB的I型光敏前药可与糖尿病慢性伤口微环境中高水平的H2O2响应释放I型光敏剂，再通过激光激发后产生PDT效应释放活性氧达到抗菌的目的，实现对糖尿病慢性创面的靶向抗感染作用，结合来源于人脐间充质干细胞的囊泡调节伤口微环境来协同治疗慢性创面；干细胞囊泡不仅能够提高光敏前药的生物相容性，同时还具有促细胞增殖、迁移及血管生成的作用；用水凝胶微针贴片装载给药的方式不仅具有高药物递送效率和微创性，同时也能提高患者的依从性。
Resumen de: CN119868310A
本发明公开了一种包埋γ‑氨基丁酸的木薯淀粉‑β‑环糊精纳米微粒的制备方法和应用，所述的制备方法包括如下步骤：步骤一）、用木薯淀粉悬浮液和β‑环糊精制备纳米微粒，再制成溶液；步骤二）、制备γ‑氨基丁酸溶液，制备得到的γ‑氨基丁酸溶液与步骤一）的纳米微粒溶液混合。本发明的γ‑氨基丁酸的木薯淀粉‑β‑环糊精纳米微粒可以提高γ‑氨基丁酸的稳定性，进一步改善γ‑氨基丁酸提高睡眠质量的效果，在医药生产中具有实际应用价值。
Resumen de: CN119868304A
本发明属于纳米技术领域，具体公开了一种具有抗菌功能的含铁脂质纳米粒IO‑LNPs的制备方法和应用。以油酸铁、大豆卵磷脂和DSPE‑MPEG2000为原料，通过梯度溶剂扩散法合成了具有抗菌功能的含铁脂质纳米粒(IO‑LNPs)，其能诱导细菌铁死亡效应，具有良好的抗菌活性，能够有效杀灭革兰氏阳性(S.aureus，)和阴性(E.coli)菌株，而且对S.aureus和E.coli具有良好的生物膜预防和破坏能力。本发明制备的具有抗菌功能的含铁脂质纳米粒IO‑LNPs在生理条件下表现出较高的稳定性和生物相容性，在抗菌性能上具有优异的效果，是对抗细菌感染和促进伤口愈合的安全高效的药剂。
Resumen de: CN119868307A
本发明涉及生物医用领域，具体提供一种杂化纳米颗粒及其制备方法、用途，旨在解决循环血液中的乳酸过多对败血症治疗过程的不良影响。为此目的，本发明的杂化纳米颗粒的制备方法包括：制备聚丙烯胺盐酸盐改性的中空介孔二氧化锰；合成柱5芳烃功能化透明质酸；在所述聚丙烯胺盐酸盐改性的中空介孔二氧化锰上负载乳酸氧化酶，得到中间体；在所述中间体的表面通过静电相互作用包被所述柱5芳烃功能化透明质酸，得到杂化纳米颗粒。本发明提供的杂化纳米颗粒制备简便、成本低廉，可广泛应用于材料学、生物学、医学等领域，具有良好的生物相容性；能够以双管齐下的乳酸清除方式有效下调循环血液乳酸浓度，有望在体内实验中有效控制LPS诱导的败血症进程。
Resumen de: AU2023337954A1
The present disclosure provides delivery vehicle compositions comprising hydroxyalkyl-capped cationic peptoids, such as 2-aminopropane-1,3-diol-capped cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for the delivery polyanionic compounds (e.g., nucleic acids) to cells. The disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the disclosure.
Resumen de: WO2024044178A1
The present disclosure relates generally to lipid nanoparticle compositions comprising a nucleic acid, an ionizable polymer, a cationic lipid, a phospholipid, a sterol, and a PEG-lipid. Further, the present disclosure relates generally to methods of treating or preventing a disease, comprising administering to a subject in need thereof a lipid nanoparticle composition described herein.
Resumen de: TW202434543A
The present application discloses a compound with a structural formula as shown in formula (I), and a salt or an isomer thereof. The present application also discloses a nanoparticle composition containing the compound and a salt or an isomer thereof. The nanoparticle composition of the present application can efficiently deliver drugs into cells and exert therapeutic or prophylactic effects of drugs.
Resumen de: CN119868309A
一种同时递送光敏剂和靶向抗体的纳米颗粒及其制备方法和应用。本发明提供的纳米颗粒，含有光敏剂、一氧化氮前体、siRNA、和巨噬细胞膜，所述光敏剂为焦脱美叶绿素a分子，所述siRNA为siPD‑L1，所述一氧化氮前体为九聚精氨酸。本发明提供的靶向纳米颗粒可实现光敏剂和siRNA的高效递送。本发明将精氨酸与焦脱镁叶绿酸a按1:1共价连接，制备纳米粒后，通过静电吸附原理负载带负电的siPD‑L1，通过包裹M1巨噬细胞膜囊泡，降低纳米颗粒表面电荷同时提高纳米颗粒的肿瘤靶向能力。在650nm激光照射下可实现光动力和抗PD‑L1免疫联合治疗恶性肿瘤。
Resumen de: TW202440536A
The present application discloses compounds of formula (I), as well as salts and stereoisomers thereof, wherein the variables are as defined in the specification. The present application also discloses nanoparticle compositions comprising the compounds or salts or stereoisomers thereof, and the use of the nanoparticle compositions for delivering active agents.
Resumen de: CN119868306A
本发明公开了一种负载过氧化铜的自佐剂化纳米药物及制备方法与应用，制备方法包括：制备酰肼化透明质酸；将酰肼化透明质酸经配位和静电吸附作用修饰于纳米氮化铝表面，得到透明质酸化纳米氮化铝；将透明质酸化纳米氮化铝通过铜‑酰肼配位/矿化反应原位制备负载过氧化铜的自佐剂化纳米药物。该纳米药物能响应肿瘤微环境发生分解，进而消耗谷胱甘肽、自供过氧化氢、自生成纳米佐剂、中和肿瘤酸性，可经氨毒性和类芬顿催化活性实现抗肿瘤治疗应用。
Resumen de: CN119874723A
本发明提出了一种近红外二区AIE探针与光激活治疗膀胱癌的纳米材料，属于材料化学技术领域，针对光热疗法对膀胱癌治疗效果不佳的问题，本发明设计了一种能够在近红外二区进行高效光热转化的AIE探针，并在其基础上将AIE探针与热敏NO供体共混，将近红外光诱导光热转换释放NO；用两亲性聚合物封装后再修饰细胞膜表面PMCA钙离子通道阻断肽和肿瘤表面FGFR1受体靶向肽，细胞膜表面PMCA钙离子通道阻断肽与热敏NO供体释放的NO共同作用，通过内源性与外源性联合调节钙离子通路，造成肿瘤钙超载，诱导肿瘤细胞凋亡；表面修饰的肿瘤表面FGFR1受体靶向肽可实现该纳米材料在肿瘤部位高效富集，提高治疗效果。本发明所提供的材料为膀胱癌治疗提供了新的思路。
Resumen de: CN119874737A
本发明公开了一种两亲性氮杂氟硼荧类荧光染料及其制备方法和应用；通过在氮杂氟硼荧类荧光结构中引入两个四甘醇作为亲水结构，引入四个C8或者C18的烷基链作为疏水基元，通过慢加水或者闪沉方式可以组装得到纳米粒子，纳米片以及支化纳米棒结构，并且这些纳米结构在808nm处有非常强的吸收，具有优异的光热转换效果，可以用于肿瘤的光热治疗。
Resumen de: CN119868308A
本发明属于生物医药技术领域，公开了一种治疗缺血性脑卒中的重组脂质纳米粒及其制备方法和应用。本发明以芹菜籽(Celery seeds，CS)为原材料采用有机溶剂提取法提取脂质，再通过乙醇注入法成功制备芹菜籽重组脂质纳米粒(CS‑rLNPs)。本发明公开的提取工艺简单，原料易得，制备的纳米药物CS‑rLNPs具有生物安全性、稳定性好等优点；经体内外实验表明，CS‑rLNPs能有效穿透血脑屏障和优先分布到缺血半暗区，并能够与脑缺血区域的神经元结合，表现出独特的神经元靶向性；除此之外，该纳米粒对缺血性脑卒中的治疗具有实用价值。因此，本发明的重组脂质纳米粒具有良好的临床应用价值和前景。
Nº publicación: CN119894499A 25/04/2025
Solicitante:
塞拉尼斯伊娃高性能聚合物公司
Resumen de: WO2023244526A1
A monolithic implantable device for delivery of an antibody is provided. The implantable device comprises a polymer matrix within which is dispersed a pharmaceutical formulation that includes one or more therapeutic agents and optionally, one or more excipients. The therapeutic agents contain an antibody and the polymer matrix contains a hydrophobic polymer. Within a time period of 35 days, the device exhibits a cumulative weight-based release ratio of the antibody of from about 20% to about 60%.
BOPI
Sede Electrónica
